Get the Stockscreener App
3.765
7.26%
0.255
Taysha Gene Therapies Inc stock is traded at $3.765, with a volume of 2.23M.
It is up +7.26% in the last 24 hours and down -25.59% over the past month.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
See More
Previous Close:
$3.51
Open:
$3.53
24h Volume:
2.23M
Relative Volume:
0.50
Market Cap:
$1.23B
Revenue:
$7.47M
Net Income/Loss:
$-129.88M
P/E Ratio:
-9.5028
EPS:
-0.3962
Net Cash Flow:
$-115.33M
1W Performance:
-15.01%
1M Performance:
-25.59%
6M Performance:
-37.25%
1Y Performance:
-29.49%
1-Day Range:
$3.50
$3.79
1-Week Range:
$3.455
$4.565
52-Week Range:
$3.455
$7.30
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
3.765 | 1.23B | 7.47M | -129.88M | -115.33M | -0.3962 |
VRTX
Vertex Pharmaceuticals Inc
|
509.86 | 129.23B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.75 | 94.92B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.00 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.32 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.60 | 42.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-26 | Initiated | Wolfe Research | Outperform |
| Oct-21-25 | Initiated | Raymond James | Strong Buy |
| Jul-11-25 | Initiated | BofA Securities | Buy |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Four new hires get Taysha stock awards tied to 384,000 shares, plus rights to buy more. - Stock Titan
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval - Seeking Alpha
These 3 Risky Stocks Could Be Sitting on 100% Upside - inkl
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution - Moomoo
Certain Common Stock of Taysha Gene Therapies, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - www.marketscreener.com
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap DownShould You Sell? - MarketBeat
TSHA-102 Rett Data, Expanded Catalent Deal And New Financing Might Change The Case For Investing In Taysha Gene Therapies (TSHA) - simplywall.st
Taysha (TSHA) Results Review: Reported EPS Misses Expectations; Trading Move: The Market Price Advances 3.96% in Latest TradingAnalyst Drop Coverage - vinanet.vn
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - AOL.com
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - The Globe and Mail
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
RA Capital reports 9.99% TSHA stake in Taysha Gene Therapies (TSHA) - Stock Titan
BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating - Moomoo
Taysha Gene Therapies (TSHA) Drops 6.5% as Gene Therapy Stock Approaches Key Support at $5.69Bull Flag - Vinanet
Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A - stocktitan.net
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6%Here's Why - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger - Yahoo Finance
Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings - MarketBeat
Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com Australia
Why is Taysha Gene Therapies stock sliding today? - Investing.com
Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com India
Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com Canada
Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside - TradingView
Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
TSHA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ... By GuruFocus - Investing.com Canada
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ... - Yahoo Finance
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlig - GuruFocus
Taysha Gene Therapies Q2 2026 Earnings Call Transcript - MarketBeat
TSHA Looks 873.5% Overvalued on GF Value™ - GuruFocus
Taysha Gene Therapies Q2 Earnings Call Highlights - MarketBeat
Taysha Gene Therapies Q2 Earnings Call Highlights - TradingView
Taysha Gene Therapies Q2 Earnings Call Highlights - Yahoo Finance
TSHA: Completed pivotal trial dosing, secured $230M financing, and advanced toward BLA submission - TradingView
Earnings call transcript: Taysha Gene Therapies misses Q2 2026 EPS forecast - Investing.com
Taysha Gene Therapies Q2 Results: Net Loss Widens To $46.6 Million - scanx.trade
Earnings Flash (TSHA) Taysha Gene Therapies Posts Q2 Loss of $0.13, vs. FactSet Est of $0.11 Loss - marketscreener.com
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - The Globe and Mail
Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Taysha Gene Therapies Q2 net loss widens on higher R&D costs - TradingView
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
Taysha Gene faces earnings test as Rett therapy advances By Investing.com - Investing.com Canada
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Taysha Gene Therapies Inc Stock (TSHA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | Officer |
Jul 10 '26 |
Proposed Sale |
6.49 |
200,000 |
1,298,000 |
0 |
| Nagendran Sukumar | President and Head of R&D |
Apr 10 '26 |
Option Exercise |
1.71 |
19,021 |
32,526 |
1,336,410 |
| Nagendran Sukumar | President and Head of R&D |
Apr 10 '26 |
Sale |
4.46 |
200,000 |
892,000 |
1,136,410 |
| Nagendran Sukumar | Officer |
Apr 10 '26 |
Proposed Sale |
4.63 |
200,000 |
926,000 |
0 |
| Rumana Haque-Ahmed | Officer |
Feb 27 '26 |
Proposed Sale |
4.57 |
2,405 |
10,991 |
0 |
| Sean McAuliffe | Affiliate - Chief Business Off |
Feb 04 '26 |
Proposed Sale |
4.72 |
914 |
4,314 |
0 |
| Kamran Alam | Officer |
Feb 04 '26 |
Proposed Sale |
4.72 |
1,655 |
7,812 |
0 |
| Alam Kamran | CHIEF FINANCIAL OFFICER |
Feb 04 '26 |
Sale |
4.52 |
1,655 |
7,481 |
1,442,131 |
| Emily McGinnis | Affiliate-Chief Pat. Adv. & |
Feb 04 '26 |
Proposed Sale |
4.72 |
901 |
4,253 |
0 |
| Fred Porter | Affiliate-Chief of Staff & |
Feb 04 '26 |
Proposed Sale |
4.72 |
889 |
4,196 |
0 |
0.44%
2.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):